CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Support legislation to reform Congressional Budget Office scoring of health care legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J. FISK | — |
| ABIGAIL LORE New | — |
| ANTHONY THEISSEN | — |
Trade (domestic/foreign) TRD
Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J. FISK | — |
| ABIGAIL LORE New | — |
| ANTHONY THEISSEN | — |
Manufacturing MAN
Support robust domestic supply chain development and manufacturing ecosystem
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J. FISK | — |
| ABIGAIL LORE New | — |
| ANTHONY THEISSEN | — |
Taxation/Internal Revenue Code TAX
Support R&D and NOL tax incentives, Orphan Drug Tax Credits Support legislation to restore the immediate expensing of research and development
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J. FISK | — |
| ABIGAIL LORE New | — |
| ANTHONY THEISSEN | — |
Medical/Disease Research/Clinical Labs MED
Support promulgation of TCET final rule Support breakthrough device coverage bill Support legislation proposing coverage for multicancer screening
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J. FISK | — |
| ABIGAIL LORE New | — |
| ANTHONY THEISSEN | — |
Copyright/Patent/Trademark CPT
Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J. FISK | — |
| ABIGAIL LORE New | — |
| ANTHONY THEISSEN | — |
Health Issues HCR
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J. FISK | — |
| ABIGAIL LORE New | — |
| ANTHONY THEISSEN | — |
Medicare/Medicaid MMM
Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Support capping Medicare beneficiary out of pocket costs Support legislation to expand and clarify the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Support improvements to manufacturer and stakeholder input processes within the Medicare Drug Price Negotiation Program Support legislation providing Medicare coverage for anti-obesity medication
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J. FISK | — |
| ABIGAIL LORE New | — |
| ANTHONY THEISSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.